Quantitative analysis of estrogen receptor heterogeneity in breast cancer

Laboratory Investigation

Volumn 87, Issue 7, 2007, Pages 662-669

  Chung, Gina G ^a   Zerkowski, Maciej P ^b   Ghosh, Sriparna ^a   Camp, Robert L ^c   Rimm, David L ^c  

^a YALE CANCER CENTER   (United States)

^b HistoRx   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Automated analysis; Breast cancer; Estrogen receptor; Quantitative analysis; Tumor heterogeneity

Indexed keywords

ESTROGEN RECEPTOR;

ARTICLE; AUTOANALYSIS; BREAST ADENOCARCINOMA; CELL HETEROGENEITY; CONTROLLED STUDY; CORRELATION ANALYSIS; GOLD STANDARD; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MEDICAL DECISION MAKING; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; STANDARDIZATION;

ADENOCARCINOMA; AUTOMATION; BREAST NEOPLASMS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; LINEAR MODELS; NEOPLASM PROTEINS; OBSERVER VARIATION; PARAFFIN EMBEDDING; PROGNOSIS; PROTEIN ARRAY ANALYSIS; RECEPTORS, ESTROGEN; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 34250352390     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700543     Document Type: Article

References (25)

1. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874.
2. Giltnane JM, Rimm DL. Technology insight: identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol 2004;1:104-111.
3. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847.
4. Anderson E, Clarke RB, Howell A. Estrogen responsiveness and control of normal human breast proliferation. J Mammary Gland Biol Neoplasia 1998;3:23-35.
5. Sommer S, Fuqua SA. Estrogen receptor and breast cancer. Semin Cancer Biol 2001;11:339-352.
6. Fisher B, Redmond C, Fisher ER, et al. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 1988;6:1076-1087.
7. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-1467.
8. Layfield LJ, Saria E, Mooney EE, et al. Tissue heterogeneity of immunohistochemically detected estrogen receptor. Implications for image analysis quantification. Am J Clin Pathol 1998;110:758-764.
9. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8:1323-1327.
10. McCabe A, Dolled-Filhart M, Camp RL, et al. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 2005;97:1808-1815.
11. Camp RL, Dolled-Filhart M, King BL, et al. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res 2003;63:1445-1448.
12. Chung GG, Yoon HH, Zerkowski MP, et al. Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer 2006;106:1677-1684.
13. Psyrri A, Yu Z, Weinberger PM, et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 2005;11:5856-5862.
14. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252-7259.
15. Leong AS, Sormunen RT, Vinyuvat S, et al. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems. Am J Clin Pathol 2001;115:709-718.
16. Douglas-Jones AG, Collett N, Morgan JM, et al. Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma. J Clin Pathol 2001;54:951-955.
17. Ono M, Sakamoto M, Ino Y, et al. Cancer cell morphology at the invasive front and expression of cell adhesion-related carbohydrate in the primary lesion of patients with colorectal carcinoma with liver metastasis. Cancer 1996;78:1179-1186.
18. Kauppila S, Stenback F, Risteli J, et al. Aberrant type I and type III collagen gene expression in human breast cancer in vivo. J Pathol 1998;186:262-268.
19. Allred DC, Bustamante MA, Daniel CO, et al. Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surg 1990;125:107-113.
20. Mann GB, Fahey VD, Feleppa F, et al. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol 2005;23:5148-5154.
21. Spataro V, Price K, Goldhirsch A, et al. Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group). Ann Oncol 1992;3:733-740.
22. Davis BW, Zava DT, Locher GW, et al. Receptor heterogeneity of human breast cancer as measured by multiple intratumoral assays of estrogen and progesterone receptor. Eur J Cancer Clin Oncol 1984;20:375-382.
23. Lluch A, Anton A, Carbonell F, et al. Intratumoral variations in cytoplasmic estrogen receptor levels in breast cancer. Breast Cancer Res Treat 1987;9:69-70.
24. Silfversward C, Skoog L, Humla S, et al. Intratumoral variation of cytoplasmic and nuclear estrogen receptor concentrations in human mammary carcinoma. Eur J Cancer 1980;16:59-65.
25. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-3816.